Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 19/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768250 | 0.91 | MAPK8 (0.69) | MAPK8MAPK9MAPK10 | |
| SCHEMBL14175797 | 0.91 | MAPK8 (0.69) | MAPK8MAPK9MAPK10 | |
| SCHEMBL14175845 | 0.87 | MAPK8 (0.69) | MAPK8MAPK9MAPK10 | |
| SCHEMBL14768230 | 0.87 | MAPK8 (0.69) | MAPK8MAPK9MAPK10 | |
| SCHEMBL14175966 | 0.87 | MAPK8 (0.62) | MAPK8MAPK9MAPK10 | |
| SCHEMBL3807198 | 0.86 | MAPK8 (0.66) | MAPK8MAPK9MAPK10 | |
| SCHEMBL3807194 | 0.86 | MAPK8 (0.66) | MAPK8MAPK9MAPK10 | |
| SCHEMBL14768145 | 0.85 | MAPK8 (0.58) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL14175820 | 0.85 | MAPK8 (0.67) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL14175967 | 0.85 | MAPK8 (0.56) | MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | MAPK8 40/4885MAPK9 43/4885MAPK10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.